| ID | 119178 |
| Author |
Yamashita, Hisako
Kanaiso Hospital
Kato, Yoshinobu
Kanaiso Hospital
Ogura, Katsunori
Kanaiso Hospital
Kato, Yoshikane
Kanaiso Hospital
|
| Keywords | Vildagliptin / Metformin (Equmet)
Imeglimin (Twymeeg)
Gastro-Intestinal Adverse Effects
Trials of Imeglimin for Efficacy and Safety
Vildagliptin Efficacy in Combination with Metformin for Early Treatment of Type 2 Diabetes
|
| Content Type |
Journal Article
|
| Description | Background: Vildagliptin/Metformin (EquMet) and imeglimin (Twymeeg) are effective oral hypoglycemic agents (OHAs) for patients with type 2 diabetes (T2D).
Case Presentation: The patient was a 68-year-old male with T2D and fatty liver for several years. In November 2022, his HbA1c had increased to 8.2%, and he was started on Twymeeg, followed by EquMet. Results: Over the course of four months, the patient’s HbA1c value successfully decreased from 8.2% to 6.7%, and he did not experience any gastrointestinal adverse effects (GIAEs). Discussion and Conclusion: The combined treatment of EquMet and Twymeeg demonstrated clinical efficacy without any adverse effects. The Trials of IMeglimin for Efficacy and Safety (TIMES) provided various evidence of imeglimin’s effectiveness. |
| Journal Title |
Asploro Journal of Biomedical and Clinical Case Reports
|
| ISSN | 25820370
|
| Publisher | Asploro
|
| Volume | 6
|
| Issue | 2
|
| Start Page | 69
|
| End Page | 75
|
| Published Date | 2023-04-14
|
| Rights | This is an open-access article distributed under the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium provided the original work is properly cited.
|
| DOI (Published Version) | |
| URL ( Publisher's Version ) | |
| FullText File | |
| language |
eng
|
| TextVersion |
Publisher
|
| departments |
Medical Sciences
|
